Discovery and characterization of FX-909, a covalent inverse agonist of PPARG rationally designed to impose a powerful repressive bias in PPARG for the treatment of PPARG/RXRA-activated muscle-invasive urothelial cancers
Jacob I. Stuckey, Jennifer A. Mertz, Jonathan E. Wilson, Kaylyn E. Williamson, Yong Li, Miljan Kuljanin, Byron DeLaBarre, Gregg Chenail, Phuong Anh Nguyen, Christopher M. Bailey, William W. Motley, James E. Audia, Robert J. Sims
bioRxiv · May 8, 2025 · PreprintCancer Biology